PDS Biotechnology (PDSB) Accounts Payables (2014 - 2026)
PDS Biotechnology's (PDSB) quarterly Accounts Payables came in at $3.6 million in Q4 2025, up 112.15% YoY from $1.7 million in Q4 2024, and down 31.01% on a QoQ basis from $5.2 million in Q3 2025.
PDS Biotechnology (PDSB) Accounts Payables (2014 - 2026) Analysis & Trends
PDS Biotechnology (PDSB) has 12 years of Accounts Payables data on file, last reported at $3.6 million in Q4 2025.
- Quarterly Accounts Payables rose 112.15% year-over-year to $3.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.6 million (up 112.15% YoY) and the FY2025 annual result came in at $3.6 million, up 112.15% from the prior year.
- Accounts Payables declined to $3.6 million in Q4 2025, from $5.2 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $7.0 million in Q4 2023 to a low of $950598.0 in Q1 2021.
- A 5-year average of $3.1 million and a median of $2.6 million in 2021 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables surged 472.7% — and 2024, when it plunged 75.87%.
- Tracing PDSB's Accounts Payables over 5 years: stood at $1.3 million in 2021, then fell by 6.88% to $1.2 million in 2022, then surged by 472.7% to $7.0 million in 2023, then sank by 75.87% to $1.7 million in 2024, then surged by 112.15% to $3.6 million in 2025.
- The last three Accounts Payables figures came in at $3.6 million (Q4 2025), $5.2 million (Q3 2025), and $4.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - | 6.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.39 Mn |
| Dec 31, 2025 | 3.57 Mn |
| Sep 30, 2025 | 5.18 Mn |
| Jun 30, 2025 | 4.50 Mn |
| Mar 31, 2025 | 2.86 Mn |
| Dec 31, 2024 | 1.68 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 3.25 Mn |
| Mar 31, 2024 | 6.00 Mn |
| Dec 31, 2023 | 6.98 Mn |
| Sep 30, 2023 | 5.37 Mn |
| Jun 30, 2023 | 4.41 Mn |
| Mar 31, 2023 | 2.07 Mn |
| Dec 31, 2022 | 1.22 Mn |
| Sep 30, 2022 | 2.04 Mn |
| Jun 30, 2022 | 1.88 Mn |
| Mar 31, 2022 | 2.75 Mn |
| Dec 31, 2021 | 1.31 Mn |
| Sep 30, 2021 | 1.45 Mn |
| Jun 30, 2021 | 2.38 Mn |